Start-up pharma company PILA PHARMA AB (PILA) addresses the issue of the global diabetes pandemia by developing an oral drug for treatment of newly diagnosed type 2 diabetic patients. The project is based on proprietary methods, and is run together with some of the world´s leading experts in clinical pharmacology, TRP- and diabetes.
PILA is based in Malmö, Sweden and was founded by CEO Dorte X. Gram in 2014 and welcomed ALMI Invest, Sweden as shareholder in January 2015.
PILA PHARMAs proprietary use-patents were spun off from Novo Nordisk A/S in 2008 when Novo Nordisk A/S decided to strategically focus on developing injectable peptide-based drugs only.
PILA aims at conducting a fast-track research & development programme of a suitable TRPV1 antagonist as novel oral anti-diabetic agent until clinical proof of concept, followed by exit.
The name PILA is Icelandic and means ‘arrow’ or ‘running fast’ reflecting the fast-track development approach and is symbolised in the PILA PHARMA logo.
Medeon Science Park
SE- 205 12 Malmö
Dorte X. Gram, CEO
Mobil: +46 (0)73 903 69 69